SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients

@article{Rosenstock2008SERENADETS,
  title={SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients },
  author={Julio Rosenstock and Priscilla Hollander and Soazig Chevalier and Ali Iranmanesh},
  journal={Diabetes Care},
  year={2008},
  volume={31},
  pages={2169 - 2176}
}
OBJECTIVE The purpose of this study was to assess the glucose-lowering efficacy and safety of rimonabant monotherapy in drug-naive type 2 diabetic patients. RESEARCH DESIGN AND METHODS The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients (SERENADE) was a 6-month, randomized, double-blind, placebo-controlled trial of 20 mg/day rimonabant in drug-naive patients with type 2 diabetes (A1C 7-10%). The primary end point was A1C change from baseline; secondary end points included… CONTINUE READING